Kuva Labs financing collapse threatens $45M Lisata Therapeutics tender offer

Kuva Labs has informed Lisata Therapeutics shareholders that financing delays are jeopardizing its tender offer for the struggling biotech, announced in early February at $1.40 per share in what was meant to be a straightforward take-private of a $32 million market-cap asset. The offer, structured as a cash tender with backstop financing commitments, has now entered indefinite limbo as Kuva's capital partners have failed to wire funds within agreed timeframes.

Lisata trades at $0.87, a 38% discount to the offer price, signaling that arbitrageurs have abandoned the spread entirely. The company's lead asset, certepetide, remains in mid-stage trials for pancreatic cancer with no near-term catalysts. Kuva, a private diagnostics firm backed by family offices in Singapore and Hong Kong, had positioned the acquisition as an intellectual property rollup play, intending to shelf the clinical program and harvest tax attributes. The financing package reportedly included $20 million in senior debt from a non-bank lender and $25 million in equity from existing Kuva backers, neither of which has closed.

The breakdown exposes how brittle pre-revenue biotech M&A has become in the current rate environment. Lisata shareholders tendered 63% of outstanding shares by the initial March 14 deadline, enough to trigger the minimum condition, but Kuva extended the offer twice while scrambling for replacement financing. The company has now burned through two extension periods without securing capital, raising questions about whether it ever had binding commitments. Lisata's board, which unanimously recommended the offer, has not withdrawn support but issued a terse statement acknowledging "ongoing discussions" with Kuva regarding "timeline adjustments."

What matters here is the evaporation of non-bank leverage for sub-$50 million biotech deals. The lender originally attached to Kuva's package, identified in regulatory filings as a Cayman-domiciled credit fund, has gone silent. Family offices that previously wrote $10 million to $30 million equity checks into take-private transactions are now requiring much steeper discounts or walking entirely. Lisata is not an outlier—three other tenders in the $20 million to $60 million range have collapsed since December, and two more are trading at spreads exceeding 30%, historically a signal of terminal doubt.

Operators and allocators should watch whether Lisata's board triggers the termination fee clause, which would force Kuva to pay $1.2 million and return tendered shares. That decision is likely within the next 10 days if Kuva cannot provide proof of funds. Separately, watch for distressed buyers circling at lower prices—Lisata's tax loss carryforwards total $180 million, still attractive to the right acquirer at $0.50 to $0.70 per share. Credit funds are also signaling they will only finance biotech M&A with asset coverage ratios exceeding 2.0x, a threshold that eliminates most pre-revenue targets.

Kuva has until March 31 under the current extension to wire funds or formally withdraw. Lisata's cash runway extends through Q3, but only if it scales back the certepetide trial.